John E. Friend II serves as Vice President, Chief Medical Officer of the Company. Dr. Friend returns to the Company bringing more than 17 years of global drug development and medical affairs expertise in hematology/oncology as well as a variety of other therapeutic indications. Most recently, he was chief medical officer of DRGT and prior to his earlier tenure at the Company, Dr. Friend served as Senior Vice President of Research and Development at Helsinn Therapeutics (U.S.), Inc. leading its research and development, clinical, medical affairs and regulatory affairs divisions. Prior to his time at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Akros Pharma, Actavis, Alpharma, Hospira and Abbott. Dr. Friend completed his post-graduate residency program in family medicine and subsequently served as Clinical Director and faculty attending physician at Cabarrus Family Medicine Residency Program in North Carolina. He earned his medical degree from UMDNJ-Robert Wood Johnson Medical School (now Rutgers, RWJMS) and received his undergraduate degree in Chemistry from Southern Methodist University.
As the Vice President e Chief Medical Officer of Cellectar Biosciences Inc, the total compensation of John Friend at Cellectar Biosciences Inc is $398,533. There are 4 executives at Cellectar Biosciences Inc getting paid more, with James Caruso having the highest compensation of $934,460.
John Friend is 47, he's been the Vice President e Chief Medical Officer of Cellectar Biosciences Inc since 2020. There are 10 older and no younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.
John's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932.
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm e John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include: